{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:56:11Z","timestamp":1781697371460,"version":"3.54.5"},"reference-count":94,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Additional value elements like productivity are currently rarely included in economic evaluations since quantitative assessment may be complex or lack clear guidance. In this study we present a practical framework for estimating the societal impact of medical interventions by incorporating additional value elements into economic evaluations.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    We applied this framework in the case of trastuzumab deruxtecan (T-DXd) for patients with metastatic breast cancer in five European countries (EU5). In this study we considered the following elements: productivity losses in paid and unpaid work, quality-adjusted life years (QALYs) valued at willingness-to-pay thresholds, the impact on childcare responsibilities, costs associated with formal caregivers, the effect on informal caregivers and impact on governmental accounts including tax revenue, pension and disability benefits.\n                    <jats:bold>Results:<\/jats:bold>\n                    Our findings indicated that some of the value elements included may lead to a positive societal value for the intervention, while others may result in additional costs. Positive impacts were seen in gains to patient productivity (\u20ac589 million), QALYs (\u20ac1.7 billion), unpaid work (\u20ac259 million), childcare responsibilities (\u20ac5 million) and tax revenue (\u20ac165 million). Conversely, our findings highlighted a greater demand for formal and informal care (-\u20ac29 million and -\u20ac7 million, respectively) and increased public spending on disability benefits (-\u20ac380 million) and pensions (-\u20ac44 million) attributed to T-DXd. The main causes of increased costs were the improvement in progression-free and overall survival achieved with T-DXd.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Overall, this framework aims to quantify the societal value of new healthcare interventions. This metastatic breast cancer case study illustrates how key value elements can be integrated into economic evaluations, beyond the classical cost\u2013effectiveness analysis, to further support reimbursement decisions.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0005","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:36:07Z","timestamp":1779446167000},"source":"Crossref","is-referenced-by-count":0,"title":["Estimating the societal impact of medical interventions: a case study in metastatic breast cancer"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-1044","authenticated-orcid":false,"given":"Foteini","family":"Tsotra","sequence":"first","affiliation":[{"name":"WifOR Institute, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Dunton","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo UK Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Rosenlund","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH, Munich, Germany"},{"name":"Department of Learning, Informatics, Management &amp; Ethics (LIME), Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Steinbeck","sequence":"additional","affiliation":[{"name":"WifOR Institute, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhvinder","family":"Johal","sequence":"additional","affiliation":[{"name":"Health Technology Assessment &amp; Modelling Science, AstraZeneca, Cambridge, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1515\/fhep-2024-0014","article-title":"Valuing the societal impact of medicines and other health technologies: a user guide to current best practices","volume":"27","author":"Shafrin J","year":"2024","unstructured":"Shafrin J, Kim J, Cohen JT Valuing the societal impact of medicines and other health technologies: a user guide to current best practices. Forum Health Econ. Policy 27(1), 29\u2013116 (2024).","journal-title":"Forum Health Econ. Policy"},{"key":"e_1_3_8_4_2","unstructured":"Hofmann S Branner J M\u00fcller M Assessing the value of medicines beyond patients' health benefit. A literature review on the concepts and methods for pharmaceutical value assessments from a societal perspective. https:\/\/insights.wifor.com\/en\/hta-download"},{"issue":"4","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","article-title":"The history and future of the \u201cISPOR Value Flower\u201d: addressing limitations of conventional cost-effectiveness analysis","volume":"25","author":"Neumann PJ","year":"2022","unstructured":"Neumann PJ, Garrison LP, Willke RJ. The history and future of the \u201cISPOR Value Flower\u201d: addressing limitations of conventional cost-effectiveness analysis. Value Health 25(4), 558\u2013565 (2022).","journal-title":"Value Health"},{"key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fpubh.2020.00049","article-title":"health impact and social value of interventions, services, and policies: a methodological discussion of health impact assessment and social return on investment methodologies","volume":"8","author":"Ashton K","year":"2020","unstructured":"Ashton K, Parry-Williams L, Dyakova M, Green L. health impact and social value of interventions, services, and policies: a methodological discussion of health impact assessment and social return on investment methodologies. Front. Public Health 8, 49 (2020).","journal-title":"Front. Public Health"},{"issue":"12","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.37765\/ajmc.2023.89468","article-title":"Generalized cost-effectiveness analysis to assess treatment value in hepatitis C","volume":"29","author":"Chou J","year":"2023","unstructured":"Chou J, Graf M. Generalized cost-effectiveness analysis to assess treatment value in hepatitis C. Am. J. Manag. Care 29(12), 696\u2013703 (2023).","journal-title":"Am. J. Manag. Care"},{"issue":"8","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jval.2022.01.025","article-title":"The impact of broader value elements on cost-effectiveness analysis: two case studies","volume":"25","author":"Ma S","year":"2022","unstructured":"Ma S, Olchanski N, Cohen JT, Ollendorf DA, Neumann PJ, Kim DD. The impact of broader value elements on cost-effectiveness analysis: two case studies. Value Health 25(8), 1336\u20131343 (2022).","journal-title":"Value Health"},{"key":"e_1_3_8_9_2","unstructured":"World Health Organisation (WHO). Breast cancer [Internet]. (2023). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"key":"e_1_3_8_10_2","unstructured":"European Cancer Information System (ECIS). Breast cancer factsheet in 2020 for EU-27 countries [Internet]. https:\/\/ecis.jrc.ec.europa.eu\/pdf\/factsheets\/Breast_cancer_en-Dec_2020.pdf"},{"key":"e_1_3_8_11_2","unstructured":"Europa Donna. Breast cancer facts [Internet]. (2022). https:\/\/www.europadonna.org\/breast-cancer\/"},{"issue":"12","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","article-title":"Economic burden of cancer across the European Union: a population-based cost analysis","volume":"14","author":"Luengo-Fernandez R","year":"2013","unstructured":"Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14(12), 1165\u20131174 (2013).","journal-title":"Lancet Oncol."},{"issue":"1","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ejhpharm-2017-001453","article-title":"The economic burden of metastatic breast cancer in Spain","volume":"27","author":"Bermejo De Las Heras B","year":"2020","unstructured":"Bermejo De Las Heras B, Cortes Ramon Y, Cajal J The economic burden of metastatic breast cancer in Spain. Eur. J. Hosp. Pharm. 27(1), 19\u201324 (2020).","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"4","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"E136","DOI":"10.1002\/ijc.29105","article-title":"Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in","volume":"136","author":"Hanly P","year":"2015","unstructured":"Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in europe. Int. J. Cancer 136(4), E136\u2013E145 (2015).","journal-title":"Int. J. Cancer"},{"issue":"1","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12962-023-00490-4","article-title":"Should additional value elements be included in cost-effectiveness analysis in pharmacoeconomic evaluation: a novel commentary","volume":"21","author":"Sun L","year":"2023","unstructured":"Sun L, Li S, Peng X. Should additional value elements be included in cost-effectiveness analysis in pharmacoeconomic evaluation: a novel commentary. Cost Eff. Resour. Alloc. 21(1), 79 (2023).","journal-title":"Cost Eff. Resour. Alloc."},{"key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"175883592311699","DOI":"10.1177\/17588359231169983","article-title":"Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer","volume":"15","author":"Yang J","year":"2023","unstructured":"Yang J, Han J, Zeng N, Yan X. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer. Ther. Adv. Med. Oncol. 15, 17588359231169983 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"e_1_3_8_17_2","unstructured":"Postma A van Schoonhoven A. Global cost-effectiveness & budget impact model for T-DXd in HER2-low metastatic and\/or unresectable breast cancer. Unpublished. Asc Academics. (2022)."},{"key":"e_1_3_8_18_2","unstructured":"Paulissen J Sloof B. Global cost-effectiveness & budget impact model for T-DXd in HER2-positive metastatic and\/or unresectable breast. Unpublished. Asc Academics. (2021)."},{"issue":"12","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s J","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386(12), 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi S","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387(1), 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_21_2","unstructured":"International Agency for research in cancer (IARC). Estimated age-standardized incidence rates (World) in 2020 breast females ages 0\u201374 [Internet]. (2020). https:\/\/gco.iarc.fr\/today\/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=20&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=14&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=0&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&show_ranking=0&rotate=%255B10%252C0%255D"},{"key":"e_1_3_8_22_2","unstructured":"Paulissen J Sloof B.Technical Report: global cost-effectiveness & budget impact model for T-DXd in HER2-positive metastatic and\/or unresectable breast. Asc Academics. (2021)."},{"key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/BCTT.S366122","article-title":"HER2-low breast cancer: current landscape and future prospects","volume":"15","author":"Shirman Y","year":"2023","unstructured":"Shirman Y, Lubovsky S, Shai A. HER2-low breast cancer: current landscape and future prospects. Breast Cancer Targets Ther. 15, 605\u2013616 (2023).","journal-title":"Breast Cancer Targets Ther."},{"issue":"1","key":"e_1_3_8_24_2","first-page":"40","article-title":"HER2-positive metastatic breast cancer: a comprehensive review","volume":"19","author":"Exman P","year":"2021","unstructured":"Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin. Adv. Hematol. Oncol. 19(1), 40\u201350 (2021).","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"5","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jval.2013.02.014","article-title":"NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified","volume":"17","author":"O'Mahony JF","year":"2014","unstructured":"O'Mahony JF, Paulden M. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified. Value Health 17(5), 493\u2013496 (2014).","journal-title":"Value Health"},{"key":"e_1_3_8_26_2","unstructured":"GOV.UK. The Green Book (2022) [Internet]. GOV.UK (2023). https:\/\/www.gov.uk\/government\/publications\/the-green-book-appraisal-and-evaluation-in-central-government\/the-green-book-2020"},{"key":"e_1_3_8_27_2","volume-title":"The societal impact of obinutuzumab in the first line treatment of patients with follicular lymphonma in Germany","author":"Hofmann S","year":"2018","unstructured":"Hofmann S, Himmler S, Ostwald DA, D\u00fcnzigner U, Launonen A, Salmen H. The societal impact of obinutuzumab in the first line treatment of patients with follicular lymphonma in Germany. ISPOR 21st Annual European Congress, Barcelona, Spain (10\u201314 November 2018)."},{"issue":"5","key":"e_1_3_8_28_2","first-page":"4291","article-title":"Unmet needs and problems related to employment and working as reported by survivors with metastatic breast cancer","volume":"30","author":"Sesto ME","year":"2022","unstructured":"Sesto ME, Carroll CB, Zhang X Unmet needs and problems related to employment and working as reported by survivors with metastatic breast cancer. Support. Care Cancer 30(5), 4291\u20134301 (2022).","journal-title":"Support. Care Cancer"},{"issue":"7","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/occmed\/kqn092","article-title":"Employment in a cohort of breast cancer patients","volume":"58","author":"Molina Villaverde R","year":"2008","unstructured":"Molina Villaverde R, Feliu Batlle J, Villalba Yllan A Employment in a cohort of breast cancer patients. Occup. Med. 58(7), 509\u2013511 (2008).","journal-title":"Occup. Med."},{"issue":"1","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12955-020-01603-w","article-title":"Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage","volume":"18","author":"Verrill M","year":"2020","unstructured":"Verrill M, Wardley AM, Retzler J Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. Health Qual. Life Outcomes 18(1), 353 (2020).","journal-title":"Health Qual. Life Outcomes"},{"issue":"2","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00420-020-01567-w","article-title":"The associations between late effects of cancer treatment, work ability and job resources: a systematic review","volume":"94","author":"Boelhouwer IG","year":"2021","unstructured":"Boelhouwer IG, Vermeer W, van Vuuren T. The associations between late effects of cancer treatment, work ability and job resources: a systematic review. Int. Arch. Occup. Environ. Health 94(2), 147\u2013189 (2021).","journal-title":"Int. Arch. Occup. Environ. Health"},{"key":"e_1_3_8_32_2","unstructured":"Federal Ministry of Labour and Social Affairs. Old age security in Germany [Internet]. http:\/\/www.bmas.de (2023). https:\/\/www.bmas.de\/EN\/Social-Affairs\/Old-age-security-in-Germany\/old-age-security-in-germany-art.html"},{"key":"e_1_3_8_33_2","unstructured":"Age UK. State Pension Advice [Internet]. Age UK (2023). https:\/\/www.ageuk.org.uk\/information-advice\/money-legal\/pensions\/state-pension\/"},{"key":"e_1_3_8_34_2","unstructured":"CLEISS. Raising the statutory retirement age to 64 in France [Internet]. (2023). https:\/\/www.cleiss.fr\/actu\/2023\/2305-raising-statutory-retirement-age-to-64-france.html"},{"key":"e_1_3_8_35_2","unstructured":"Ministerio de Inclusion Securidad Social Y Migraciones. Seguridad social: benefits \/ pensions for workers [Internet]. https:\/\/www.seg-social.es\/wps\/portal\/wss\/internet\/Trabajadores\/PrestacionesPensionesTrabajadores\/10963\/28393\/28396\/28472"},{"key":"e_1_3_8_36_2","unstructured":"European Commission. Italy - Employment Social Affairs & Inclusion - European Commission [Internet]. (2023). https:\/\/ec.europa.eu\/social\/main.jsp?catId=1116&langId=en&intPageId=4625"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0077"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0131"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.05.002"},{"key":"e_1_3_8_40_2","unstructured":"WifOR Institute. Glossary. Health Economics. [Internet]. https:\/\/insights.wifor.com\/en\/glossary-health-economics"},{"key":"e_1_3_8_41_2","volume-title":"Economics of household production","author":"Reid MG","year":"2021","unstructured":"Reid MG. Economics of household production. J. Wiley & Sons, NY, USA (2021)."},{"issue":"1","key":"e_1_3_8_42_2","first-page":"213","article-title":"Economics of Household Production","volume":"178","author":"Reid M","year":"1935","unstructured":"Reid M. Economics of Household Production. Ann. Am. Acad. Pol. Soc. Sci. 178(1), 213 (1935).","journal-title":"Ann. Am. Acad. Pol. Soc. Sci."},{"key":"e_1_3_8_43_2","doi-asserted-by":"crossref","unstructured":"Ferrant G Pesando LM Nowacka K. Unpaid Care Work: the missing link in the analysis of gender gaps in labour outcomes [Internet]. (2014). https:\/\/www.oecd.org\/dev\/development-gender\/Unpaid_care_work.pdf","DOI":"10.1787\/1f3fd03f-en"},{"key":"e_1_3_8_44_2","unstructured":"Eurostat. Zeitverwendung Teilnahmezeit und Teilnahmerate f\u00fcr die Hauptaktivit\u00e4t nach Geschlecht und Altersgruppe [Internet]. (2023). https:\/\/ec.europa.eu\/eurostat\/web\/products-datasets\/-\/tus_00age"},{"key":"e_1_3_8_45_2","unstructured":"Eurostat. Overview - Harmonised European Time Use Surveys (HETUS) - Eurostat [Internet]. (2024). https:\/\/ec.europa.eu\/eurostat\/web\/time-use-surveys"},{"key":"e_1_3_8_46_2","unstructured":"Office for National Statistics (ONS). Unpaid work calculator (based on household satellite accounts and annual survey of hours and earnings). (2016)."},{"issue":"10","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3111\/13696998.2013.826228","article-title":"Indirect costs associated with metastatic breast cancer","volume":"16","author":"Wan Y","year":"2013","unstructured":"Wan Y, Gao X, Mehta S, Wang Z, Faria C, Schwartzberg L. Indirect costs associated with metastatic breast cancer. J. Med. Econ. 16(10), 1169\u20131178 (2013).","journal-title":"J. Med. Econ."},{"issue":"18","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1002\/cncr.24588","article-title":"Time costs associated with informal caregiving for cancer survivors","volume":"115","author":"Yabroff KR","year":"2009","unstructured":"Yabroff KR, Kim Y. Time costs associated with informal caregiving for cancer survivors. Cancer 115(Suppl. 18), 4362\u20134373 (2009).","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1186\/s12913-017-2594-4","article-title":"The utilization of formal and informal home care by older patients with cancer: a Belgian cohort study with two control groups","volume":"17","author":"Baitar A","year":"2017","unstructured":"Baitar A, Buntinx F, De Burghgraeve T The utilization of formal and informal home care by older patients with cancer: a Belgian cohort study with two control groups. BMC Health Serv. Res. 17(1), 644 (2017).","journal-title":"BMC Health Serv. Res."},{"key":"e_1_3_8_50_2","unstructured":"NHS. Paying for your own care (self-funding) [Internet]. (2022). https:\/\/www.nhs.uk\/conditions\/social-care-and-support-guide\/money-work-and-benefits\/paying-for-your-own-care-self-funding\/"},{"key":"e_1_3_8_51_2","unstructured":"SalaryExpert (ERI Economic Research Institute). Salary data and compensation estimates by job and location. [Internet]. https:\/\/www.salaryexpert.com\/salary"},{"issue":"1","key":"e_1_3_8_52_2","doi-asserted-by":"crossref","first-page":"101375","DOI":"10.1016\/j.esmoop.2023.101375","article-title":"186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized Phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2\u2013positive (HER2+) metastatic breast cancer (mBC)","volume":"8","author":"Fehm TN","year":"2023","unstructured":"Fehm TN, Cottone F, Dunton K 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized Phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2\u2013positive (HER2+) metastatic breast cancer (mBC). ESMO Open 8(1), 101375 (2023).","journal-title":"ESMO Open"},{"key":"e_1_3_8_53_2","doi-asserted-by":"crossref","first-page":"S632","DOI":"10.1016\/j.annonc.2022.07.256","article-title":"217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized Phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)","volume":"33","author":"Ueno NT","year":"2022","unstructured":"Ueno NT, Jacot W, Yamashita T 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized Phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC). Ann. Oncol. 33, S632\u2013S633 (2022).","journal-title":"Ann. Oncol."},{"issue":"7","key":"e_1_3_8_54_2","doi-asserted-by":"crossref","first-page":"A492","DOI":"10.1016\/j.jval.2016.09.843","article-title":"Is there evidence of a difference between willingness to pay and willingness to accept thresholds? A review of NICE Technology Appraisals","volume":"19","author":"Minacori R","year":"2016","unstructured":"Minacori R, Geale K, Geale K. Is there evidence of a difference between willingness to pay and willingness to accept thresholds? A review of NICE Technology Appraisals. Value Health 19(7), A492\u2013A493 (2016).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_8_55_2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.14283\/jpad.2022.53","article-title":"Evaluation of the fiscal costs and consequences of Alzheimer's disease in Germany: microsimulation of patients' and caregivers' pathways","volume":"9","author":"Martins R","year":"2022","unstructured":"Martins R, Kotsopoulos N, Michalowsky B, Pemberton-Ross P, Urbich M, Connolly MP. Evaluation of the fiscal costs and consequences of Alzheimer's disease in Germany: microsimulation of patients' and caregivers' pathways. J. Prev. Alzheimers Dis. 9(4), 758\u2013768 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"3","key":"e_1_3_8_56_2","doi-asserted-by":"crossref","first-page":"E495","DOI":"10.3390\/vaccines8030495","article-title":"Estimating the fiscal consequences of National Immunization Programs using a \u201cGovernment Perspective\u201d public economic framework","volume":"8","author":"Connolly MP","year":"2020","unstructured":"Connolly MP, Kotsopoulos N. Estimating the fiscal consequences of National Immunization Programs using a \u201cGovernment Perspective\u201d public economic framework. Vaccines 8(3), E495 (2020).","journal-title":"Vaccines"},{"issue":"1","key":"e_1_3_8_57_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/13696998.2021.1873004","article-title":"Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia","volume":"24","author":"Kotsopoulos N","year":"2021","unstructured":"Kotsopoulos N, Connolly MP, Li J. Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia. J. Med. Econ. 24(1), 123\u2013130 (2021).","journal-title":"J. Med. Econ."},{"key":"e_1_3_8_58_2","unstructured":"Federal Ministry of Labour and Social Affairs. Labour and Social Affairs [Internet]. (2023). https:\/\/www.bmas.de\/EN\/Home\/home.html"},{"key":"e_1_3_8_59_2","unstructured":"l'Assurance Maladie. ameli le site de l'Assurance Maladie en ligne | ameli.fr | Assur\u00e9 [Internet]. (2023). https:\/\/www.ameli.fr\/assure"},{"key":"e_1_3_8_60_2","unstructured":"Seguridad Social. Social security: internet [Internet]. https:\/\/www.seg-social.es\/wps\/portal\/wss\/internet\/Inicio"},{"key":"e_1_3_8_61_2","unstructured":"National Institute for Social Security (INPS). Social security [Internet]. Sito Uff. INPS Ist. Naz. Previd. Soc. https:\/\/www.inps.it"},{"key":"e_1_3_8_62_2","unstructured":"OECD. OECD Statistics [Internet]. (2021). https:\/\/stats.oecd.org\/"},{"key":"e_1_3_8_63_2","unstructured":"OECD. Tax - Tax wedge - OECD Data [Internet]. The OECD. http:\/\/data.oecd.org\/tax\/tax-wedge.htm"},{"key":"e_1_3_8_64_2","unstructured":"PwC. Italy - Corporate - Other taxes [Internet]. (2023). https:\/\/taxsummaries.pwc.com\/italy\/corporate\/other-taxes"},{"key":"e_1_3_8_65_2","unstructured":"GOV.UK. VAT rates [Internet]. GOV.UK (2023). https:\/\/www.gov.uk\/vat-rates"},{"key":"e_1_3_8_66_2","unstructured":"PwC. Spain - Corporate - Other taxes [Internet]. (2023). https:\/\/taxsummaries.pwc.com\/spain\/corporate\/other-taxes"},{"key":"e_1_3_8_67_2","unstructured":"PwC. Germany - Corporate - Other taxes [Internet]. (2023). https:\/\/taxsummaries.pwc.com\/germany\/corporate\/other-taxes"},{"key":"e_1_3_8_68_2","unstructured":"PwC. France - Corporate - Other taxes [Internet]. (2023). https:\/\/taxsummaries.pwc.com\/france\/corporate\/other-taxes"},{"key":"e_1_3_8_69_2","unstructured":"OECD Better Life Index. Italy - how's life [Internet]. (2023). https:\/\/www.oecdbetterlifeindex.org\/countries\/italy\/"},{"key":"e_1_3_8_70_2","unstructured":"Nomis - Official Census and Labour Market Statistics. Regional gross disposable household income - [Internet]. (2023). https:\/\/www.nomisweb.co.uk\/datasets\/gdhi"},{"key":"e_1_3_8_71_2","unstructured":"INE base. Standard of living and living conditions (CPI) \/Living conditions \/Household Budget Survey. Base 2006\/Latest data [Internet]. INE. https:\/\/www.ine.es\/dyngs\/INEbase\/en\/operacion.htm?c=Estadistica_C&cid=1254736176806&menu=ultiDatos&idp=1254735976608"},{"key":"e_1_3_8_72_2","article-title":"Income, receipts and expenditure of households by territory [Internet]","author":"Destatis","year":"2023","unstructured":"Destatis. Income, receipts and expenditure of households by territory [Internet]. Fed. Stat. Off. (2023). https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Income-Consumption-Living-Conditions\/Income-Receipts-Expenditure\/Tables\/liste-Income-receipts-expenditure-households.html","journal-title":"Fed. Stat. Off."},{"key":"e_1_3_8_73_2","unstructured":"Statista. France: household disposable income [Internet]. (2023). https:\/\/www.statista.com\/statistics\/513021\/average-annual-household-disposable-income-france\/"},{"key":"e_1_3_8_74_2","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA). The pharmaceutical industry in figures_key data [Internet]. https:\/\/www.efpia.eu\/media\/uj0popel\/the-pharmaceutical-industry-in-figures-2025.pdf"},{"key":"e_1_3_8_75_2","unstructured":"IQVIA. The Global Use of Medicines Outlook Through 2029 [Internet]. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-global-use-of-medicines-outlook-through-2029"},{"key":"e_1_3_8_76_2","unstructured":"Institute for Clinical and Economic Review (ICER). Health Economics Methods Advisory Group selects first area for study: assessing treatment benefits appropriate to consider in HTA decision-making [Internet]. (2024). https:\/\/icer.org\/news-insights\/press-releases\/health-economics-methods-advisory-group-selects-first-area-for-study-assessing-treatment-benefits-appropriate-to-consider-in-hta-decision-making\/"},{"key":"e_1_3_8_77_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CEOR.S191382","article-title":"The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology","volume":"11","author":"Retzler J","year":"2019","unstructured":"Retzler J, Davies H, Jenks M, Kiff C, Taylor M. The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology. Clin. Outcomes Res. 11, 309\u2013324 (2019).","journal-title":"Clin. Outcomes Res."},{"key":"e_1_3_8_78_2","unstructured":"OECD. Stat. Healthcare resources: remuneration of health professionals [Internet]. (2023). https:\/\/stats.oecd.org\/index.aspx?queryid=30025"},{"key":"e_1_3_8_79_2","unstructured":"OECD. Pharmaceutical spending [Internet]. (2023). https:\/\/data.oecd.org\/healthres\/pharmaceutical-spending.htm"},{"issue":"6","key":"e_1_3_8_80_2","first-page":"589","article-title":"Female breast cancer in Europe: statistics, diagnosis and treatment modalities","volume":"6","author":"Zagouri F","year":"2014","unstructured":"Zagouri F, Sergentanis TN, Tsigginou A Female breast cancer in Europe: statistics, diagnosis and treatment modalities. J. Thorac. Dis. [Internet] 6(6), 589 (2014). https:\/\/jtd.amegroups.org\/article\/view\/2662","journal-title":"J. Thorac. Dis. [Internet]"},{"key":"e_1_3_8_81_2","unstructured":"European Society of Breast Cancer Specialists (EUSOMA). About Us [Internet]. (2023). https:\/\/www.eusoma.org\/en\/about%2dus\/1-105-1"},{"key":"e_1_3_8_82_2","unstructured":"European Commission. Public Health [Internet]. (2023). https:\/\/health.ec.europa.eu\/eu-health-policy\/overview_en"},{"issue":"10","key":"e_1_3_8_83_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/bs11100135","article-title":"Experiences of female breast cancer survivors concerning their return to work in Spain","volume":"11","author":"Aguiar-Fern\u00e1ndez F","year":"2021","unstructured":"Aguiar-Fern\u00e1ndez F, Rodr\u00edguez-Castro Y, Botija M, Mart\u00ednez-Rom\u00e1n R. Experiences of female breast cancer survivors concerning their return to work in Spain. Behav. Sci. 11(10), 135 (2021).","journal-title":"Behav. Sci."},{"key":"e_1_3_8_84_2","unstructured":"Gobierno de Espana. Procedures and formalities \u2013 temporary disability benefits [Internet]. (2023). https:\/\/www.seg-social.es\/wps\/portal\/wss\/internet\/InformacionUtil\/44539\/44667"},{"key":"e_1_3_8_85_2","unstructured":"Gobierno de Espana. Procedures and formalities \u2013 permanent disability pension [Internet]. (2023). https:\/\/www.seg-social.es\/wps\/portal\/wss\/internet\/InformacionUtil\/44539\/45982"},{"key":"e_1_3_8_86_2","article-title":"Sick Leave UK: laws, pay and how to build a sickness and absence policy [Internet]","author":"Baigey E","year":"2023","unstructured":"Baigey E. Sick Leave UK: laws, pay and how to build a sickness and absence policy [Internet]. Factorial (2023). https:\/\/factorialhr.co.uk\/blog\/sick-leave-uk\/","journal-title":"Factorial"},{"key":"e_1_3_8_87_2","article-title":"Social security in Italy [Internet]","author":"Maunder S","year":"2023","unstructured":"Maunder S. Social security in Italy [Internet]. Expatica (2023). https:\/\/www.expatica.com\/it\/living\/gov-law-admin\/social-security-italy-82918\/","journal-title":"Expatica"},{"key":"e_1_3_8_88_2","article-title":"Employee benefits in France: a guide to mandatory and common benefits [Internet]","author":"Velocity Global","year":"2023","unstructured":"Velocity Global. Employee benefits in France: a guide to mandatory and common benefits [Internet]. Veloc. Glob. (2023). https:\/\/velocityglobal.com\/resources\/blog\/employee-benefits-in-france\/","journal-title":"Veloc. Glob."},{"key":"e_1_3_8_89_2","unstructured":"OECD. Sickness disability and work: breaking the barriers: a synthesis of findings across OECD countries [Internet]. OECD. https:\/\/www.oecd.org\/en\/publications\/sickness-disability-and-work-breaking-the-barriers_9789264088856-en.html"},{"issue":"2","key":"e_1_3_8_90_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jval.2016.11.018","article-title":"The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework","volume":"20","author":"Connolly MP","year":"2017","unstructured":"Connolly MP, Kotsopoulos N, Postma MJ, Bhatt A. The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health 20(2), 273\u2013277 (2017).","journal-title":"Value Health"},{"key":"e_1_3_8_91_2","unstructured":"NICE. The National Institute for Health and Care Excellence [Internet]. (2024). https:\/\/www.nice.org.uk\/"},{"key":"e_1_3_8_92_2","unstructured":"HAS. Economic and Public Health Evaluation Committee [Internet]. (2024). https:\/\/www.has-sante.fr\/jcms\/c_2036304\/en\/economic-and-public-health-evaluation-committee"},{"key":"e_1_3_8_93_2","unstructured":"G-BA. Gemeinsamer Bundesausschuss [Internet]. (2024). https:\/\/www.g-ba.de\/"},{"key":"e_1_3_8_94_2","unstructured":"HAS. Haute Autorit\u00e9 de Sant\u00e9 [Internet]. (2024). https:\/\/www.has-sante.fr\/"},{"key":"e_1_3_8_95_2","unstructured":"AEMPS. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios [Internet]. (2024). https:\/\/www.aemps.gob.es\/"},{"key":"e_1_3_8_96_2","unstructured":"AIFA. Agenzia Italiana del Farmaco [Internet]. (2024). https:\/\/www.aifa.gov.it\/"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:20:42Z","timestamp":1781695242000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.57264\/cer-2026-0005"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0005","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e260005"}}